miR‑149‑3p suppresses the proliferation and metastasis of glioma cells by targeting the CBX2/Wnt/β‑catenin pathway

Wang,Yanjun; Song,Yanqun; Liu,Zhongcheng; Li,Junmin; Wang,Guodong; Pan,Hong; Zheng,Zhiming

doi:10.3892/etm.2023.12261

miR‑149‑3p suppresses the proliferation and metastasis of glioma cells by targeting the CBX2/Wnt/β‑catenin pathway

Authors:
- Yanjun Wang
- Yanqun Song
- Zhongcheng Liu
- Junmin Li
- Guodong Wang
- Hong Pan
- Zhiming Zheng
View Affiliations

Affiliations: Department of Neurosurgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R. China, Department of Neurosurgery, The Third People's Hospital of Heze City, Heze, Shandong 274031, P.R. China, Department of Neurosurgery, The First People's Hospital of Tai'an, Tai'an, Shandong 271000, P.R. China, Department of Obstetrics and Gynecology, Jinan Maternity and Child Care Hospital, Jinan, Shandong 250021, P.R. China, Department of Ophthalmology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong 250021, P.R. China
Published online on: October 19, 2023 https://doi.org/10.3892/etm.2023.12261
Article Number: 562
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the role of miR‑149‑3p/chromobox 2 (CBX2)/Wnt/β‑catenin pathway in the proliferation and metastasis of glioma cells. The expression and clinical significance of miR‑149‑3p and CBX2 were analyzed using data from public databases. Cell Counting Kit‑8 and colony formation assays were performed to measure cell proliferation. Transwell assays were used to assess cell invasion. The results showed that miR‑149‑3p was downregulated and CBX2 was upregulated in glioma, and that the downregulated expression of miR‑149‑3p promoted the proliferation and invasion of glioma cells. In addition, downregulated expression of CBX2 suppressed the proliferation and invasion of glioma cells. Dual‑luciferase assay indicated that CBX2 is a target gene of miR149‑3p. The possible molecular mechanism of CBX2 was probed by western blotting, which showed that it may further affect the Wnt/β‑catenin pathway. These present findings demonstrated that miR‑149‑3p may function as a tumor suppressor miRNA by directly regulating CBX2 and serve important roles in the malignancy of glioma.

View Figures

View References

1	Miller KD, Ostrom QT, Kruchko C, Patil N, Tihan T, Cioffi G, Fuchs HE, Waite KA, Jemal A, Siegel RL and Barnholtz-Sloan JS: Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 71:381–406. 2021.PubMed/NCBI View Article : Google Scholar
2	Chen R, Smith-Cohn M, Cohen AL and Colman H: Glioma subclassifications and their clinical significance. Neurotherapeutics. 14:284–297. 2017.PubMed/NCBI View Article : Google Scholar
3	Montella L, Cuomo M, Del Gaudio N, Buonaiuto M, Costabile D, Visconti R, Di Risi T, Vinciguerra R, Trio F, Ferraro S, et al: Epigenetic alterations in glioblastomas: Diagnostic, prognostic and therapeutic relevance. Int J Cancer. 153:476–488. 2023.PubMed/NCBI View Article : Google Scholar
4	Kannan S, Murugan AK, Balasubramanian S, Munirajan AK and Alzahrani AS: Gliomas: Genetic alterations, mechanisms of metastasis, recurrence, drug resistance, and recent trends in molecular therapeutic options. Biochem Pharmacol. 201(115090)2022.PubMed/NCBI View Article : Google Scholar
5	Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Rådmark O, Kim S and Kim VN: The nuclear RNase III Drosha initiates microRNA processing. Nature. 425:415–419. 2003.PubMed/NCBI View Article : Google Scholar
6	Banelli B, Forlani A, Allemanni G, Morabito A, Pistillo MP and Romani M: MicroRNA in glioblastoma: An overview. Int J Genomics. 2017(7639084)2017.PubMed/NCBI View Article : Google Scholar
7	Murugan AK, Munirajan AK and Alzahrani AS: MicroRNAs: Modulators of the Ras oncogenes in oral cancer. J Cell Physiol. 231:1424–1431. 2016.PubMed/NCBI View Article : Google Scholar
8	Dai L, Liang W, Shi Z, Li X, Zhou S, Hu W, Yang Z and Wang X: Systematic characterization and biological functions of non-coding RNAs in glioblastoma. Cell Prolif. 56(e13375)2023.PubMed/NCBI View Article : Google Scholar
9	Moore LM, Kivinen V, Liu Y, Annala M, Cogdell D, Liu X, Liu CG, Sawaya R, Yli-Harja O, Shmulevich I, et al: Transcriptome and small RNA deep sequencing reveals deregulation of miRNA biogenesis in human glioma. J Pathol. 229:449–459. 2013.PubMed/NCBI View Article : Google Scholar
10	Behrooz AB, Latifi-Navid H, Nezhadi A, Świat M, Los M, Jamalpoor Z and Ghavami S: Molecular mechanisms of microRNAs in glioblastoma pathogenesis. Biochim Biophys Acta Mol Cell Res. 1870(119482)2023.PubMed/NCBI View Article : Google Scholar
11	Anthiya S, Griveau A, Loussouarn C, Baril P, Garnett M, Issartel JP and Garcion E: MicroRNA-based drugs for brain tumors. Trends Cancer. 4:222–238. 2018.PubMed/NCBI View Article : Google Scholar
12	Yin J, Ge X, Shi Z, Yu C, Lu C, Wei Y, Zeng A, Wang X, Yan W, Zhang J and You Y: Extracellular vesicles derived from hypoxic glioma stem-like cells confer temozolomide resistance on glioblastoma by delivering miR-30b-3p. Theranostics. 11:1763–1779. 2021.PubMed/NCBI View Article : Google Scholar
13	Lei Q, Yang Y, Zhou W, Liu W, Li Y, Qi N, Li Q, Wen Z, Ding L, Huang X, et al: MicroRNA-based therapy for glioblastoma: Opportunities and challenges. Eur J Pharmacol. 938(175388)2023.PubMed/NCBI View Article : Google Scholar
14	Clermont PL, Sun L, Crea F, Thu KL, Zhang A, Parolia A, Lam WL and Helgason CD: Genotranscriptomic meta-analysis of the Polycomb gene CBX2 in human cancers: Initial evidence of an oncogenic role. Br J Cancer. 111:1663–1672. 2014.PubMed/NCBI View Article : Google Scholar
15	Del Gaudio N, Di Costanzo A, Liu NQ, Conte L, Dell'Aversana C, Bove G, Benedetti R, Montella L, Ciardiello F, Carafa V, et al: CBX2 shapes chromatin accessibility promoting AML via p38 MAPK signaling pathway. Mol Cancer. 21(125)2022.PubMed/NCBI View Article : Google Scholar
16	Bilton LJ, Warren C, Humphries RM, Kalsi S, Waters E, Francis T, Dobrowinski W, Beltran-Alvarez P and Wade MA: The epigenetic regulatory protein CBX2 promotes mTORC1 signalling and inhibits DREAM complex activity to drive breast cancer cell growth. Cancers (Basel). 14(3491)2022.PubMed/NCBI View Article : Google Scholar
17	Zhou H, Xiong Y, Liu Z, Hou S and Zhou T: Expression and prognostic significance of CBX2 in colorectal cancer: Database mining for CBX family members in malignancies and vitro analyses. Cancer Cell Int. 21(402)2021.PubMed/NCBI View Article : Google Scholar
18	Gulluoglu S, Tuysuz EC, Sahin M, Kuskucu A, Kaan Yaltirik C, Ture U, Kucukkaraduman B, Akbar MW, Gure AO, Bayrak OF and Dalan AB: . Simultaneous miRNA and mRNA transcriptome profiling of glioblastoma samples reveals a novel set of OncomiR candidates and their target genes. Brain Res. 1700:199–210. 2018.PubMed/NCBI View Article : Google Scholar
19	Huang T, Yang Y, Song X, Wan X, Wu B, Sastry N, Horbinski CM, Zeng C, Tiek D, Goenka A, et al: PRMT6 methylation of RCC1 regulates mitosis, tumorigenicity, and radiation response of glioblastoma stem cells. Mol Cell. 81:1276–1291. 2021.PubMed/NCBI View Article : Google Scholar
20	Dalby B, Cates S, Harris A, Ohki EC, Tilkins ML, Price PJ and Ciccarone VC: Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods. 33:95–103. 2004.PubMed/NCBI View Article : Google Scholar
21	Liang A, Zhou B and Sun W: Integrated genomic characterization of cancer genes in glioma. Cancer Cell Int. 17(90)2017.PubMed/NCBI View Article : Google Scholar
22	Jonsson P, Lin AL, Young RJ, DiStefano NM, Hyman DM, Li BT, Berger MF, Zehir A, Ladanyi M, Solit DB, et al: Genomic correlates of disease progression and treatment response in prospectively characterized gliomas. Clin Cancer Res. 25:5537–5547. 2019.PubMed/NCBI View Article : Google Scholar
23	Zuo J, Yu H, Xie P, Liu W, Wang K and Ni H: miR-454-3p exerts tumor-suppressive functions by down-regulation of NFATc2 in glioblastoma. Gene. 710:233–239. 2019.PubMed/NCBI View Article : Google Scholar
24	Zhou F, Cao W, Xu R, Zhang J, Yu T, Xu X, Zhi T, Yin J, Cao S, Liu N, et al: MicroRNA-206 attenuates glioma cell proliferation, migration, and invasion by blocking the WNT/β-catenin pathway via direct targeting of Frizzled 7 mRNA. Am J Transl Res. 11:4584–4601. 2019.PubMed/NCBI
25	Bian Z, Ji W, Xu B, Huo Z, Huang H, Huang J, Jiao J, Shao J and Zhang X: Noncoding RNAs involved in the STAT3 pathway in glioma. Cancer Cell Int. 21(445)2021.PubMed/NCBI View Article : Google Scholar
26	Chan SH, Huang WC, Chang JW, Chang KJ, Kuo WH, Wang MY, Lin KY, Uen YH, Hou MF, Lin CM, et al: MicroRNA-149 targets GIT1 to suppress integrin signaling and breast cancer metastasis. Oncogene. 33:4496–4507. 2014.PubMed/NCBI View Article : Google Scholar
27	Cao D, Jia Z, You L, Wu Y, Hou Z, Suo Y, Zhang H, Wen S, Tsukamoto T, Oshima M, et al: 18β-glycyrrhetinic acid suppresses gastric cancer by activation of miR-149-3p-Wnt-1 signaling. Oncotarget. 7:71960–71973. 2016.PubMed/NCBI View Article : Google Scholar
28	Okato A, Arai T, Yamada Y, Sugawara S, Koshizuka K, Fujimura L, Kurozumi A, Kato M, Kojima S, Naya Y, et al: Dual strands of pre-miR-149 inhibit cancer cell migration and invasion through targeting FOXM1 in renal cell carcinoma. Int J Mol Sci. 18(1969)2017.PubMed/NCBI View Article : Google Scholar
29	Fan SJ, Li HB, Cui G, Kong XL, Sun LL, Zhao YQ, Li YH and Zhou J: miRNA-149* promotes cell proliferation and suppresses apoptosis by mediating JunB in T-cell acute lymphoblastic leukemia. Leuk Res. 41:62–70. 2016.PubMed/NCBI View Article : Google Scholar
30	Long C, Jiang L, Wei F, Ma C, Zhou H, Yang S, Liu X and Liu Z: Integrated miRNA-mRNA analysis revealing the potential roles of miRNAs in chordomas. PLoS One. 8(e66676)2013.PubMed/NCBI View Article : Google Scholar
31	Kaustov L, Ouyang H, Amaya M, Lemak A, Nady N, Duan S, Wasney GA, Li Z, Vedadi M, Schapira M, et al: Recognition and specificity determinants of the human cbx chromodomains. J Biol Chem. 286:521–529. 2011.PubMed/NCBI View Article : Google Scholar
32	Clermont PL, Crea F, Chiang YT, Lin D, Zhang A, Wang JZ, Parolia A, Wu R, Xue H, Wang Y, et al: Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer. Clin Epigenetics. 8(16)2016.PubMed/NCBI View Article : Google Scholar
33	Wheeler LJ, Watson ZL, Qamar L, Yamamoto TM, Post MD, Berning AA, Spillman MA, Behbakht K and Bitler BG: CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer. Oncogenesis. 7(92)2018.PubMed/NCBI View Article : Google Scholar
34	Jangal M, Lebeau B and Witcher M: Beyond EZH2: Is the polycomb protein CBX2 an emerging target for anti-cancer therapy? Expert Opin Ther Targets. 23:565–578. 2019.PubMed/NCBI View Article : Google Scholar